D202 Continued Safety/Efficacy of Omalizumab in Chronic Rhinosinusitis With Nasal Polyps: An Open-Label Extension Study

What is the contribution of IgE to nasal polyposis?

“…Omalizumab, as add on to intranasal corticosteroids, was associated with significant reductions in nasal polyp and nasal congestion scores over 24 weeks, 14 with these improvements sustained over 52 weeks in an open-label extension study. 72 Collectively, these clinical data confirm the role of IgE in nasal polyposis pathophysiology. 14 Recently, omalizumab has been approved in many countries as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRS with nasal polyps for whom therapy with intranasal corticosteroids does not provide adequate disease control.…”

Chronic Rhinosinusitis With Nasal Polyps: Quality of Life in the Biologics Era

“…86 These results were maintained for 76 weeks in the associated open-label extension study, with additional sleep improvements observed at 24 to 52 weeks. 118,119 Finally, a multicenter retrospective study echoed the drug's efficacy. Improvements in QoL were seen in patients with comorbid CRSwNP, asthma, and AERD.…”

Multidisciplinary consensus on a stepwise treatment algorithm for management of chronic rhinosinusitis with nasal polyps

“…However, when omalizumab was discontinued at week 52, there was gradual worsening of the key measurements during the withdrawal period. During the open label study, the CRSwNP subjects who initially received omalizumab continued to improve in NPS, NCS, and SNOT‐22 through week 52 16 . In the open label study for omalizumab, the initial placebo group experienced rapid and large improvements after administration of omalizumab.…”

“…Significant change in NPS was observed between treatment and placebo groups for POLYP 1 (−1.08 vs. 0.06, p < 0. 16 In the open label study for omalizumab, the initial placebo group experienced rapid and large improvements after administration of omalizumab. However, when omalizumab was discontinued at week 52, there was gradual worsening of the key measurements during the withdrawal period.…”